BioNTech's Double Exodus: Founders Exit as Factory Doors Close, Piling Pressure on a $19.6 Billion Cancer Bet

The Mainz-based vaccine pioneer is undergoing its most radical transformation since the pandemic, and the upheaval is coming from two directions at once. By the end of 2027, BioNTech will have shuttered all of its German production sites for Covid-19 shots, and by year-end 2026, its founding duo – Ugur Sahin and Özlem Türeci – will have vacated their executive roles. The simultaneous leadership and operational overhaul places enormous weight on the company's oncology pipeline to justify the restructuring.

The economic rationale is blunt. In the first quarter, revenue slumped to €118.1 million from €182.8 million a year earlier, while the net loss ballooned to €531.9 million. Research and development spending alone topped $650 million as the company funneled cash into clinical trials for candidates such as pumitamig and gotistobart. Yet BioNTech sits on a comfortable cash pile of $19.6 billion, and management has reaffirmed full-year revenue guidance of between $2.3 billion and $2.6 billion. A $1 billion share buyback programme, authorised over a 12-month period, is designed to signal confidence amid the noise.

The production retreat is comprehensive. BioNTech will close its sites in Idar-Oberstein, Marburg and Tübingen by the end of 2027, with partner Pfizer taking over all future manufacturing of its Covid-19 vaccines. The Singapore facility will follow, winding down in the first quarter of 2027. A company spokesperson confirmed that the last doses made in Germany will be produced this year. Chief financial officer Ramón Zapata framed the move as a response to capacity that would otherwise sit empty or underutilised within 24 months. The restructuring, announced in May 2026, includes a 22% reduction in headcount – the deepest cut since the company went public.

Political fallout came swiftly. The federal government insisted that alternative manufacturers could fill the gap and that vaccine supply to the population would remain secure. On the ground, Tübingen's mayor Boris Palmer expressed shock, accusing BioNTech of breaking trust in regional development pledges. The sting is particularly sharp in Tübingen, because BioNTech acquired that facility only in January 2026 as part of its takeover of CureVac. CureVac founder Ingmar Hoerr claimed the company had been deceived and that the transaction should never have gone ahead.

Should investors sell immediately? Or is it worth buying BioNTech?

At the top of the organisation, a different kind of departure is unfolding. Sahin and Türeci, who respectively serve as chief executive and chief medical officer, will step down at the end of 2026 to launch a new biotechnology venture focused on next-generation messenger RNA innovations. BioNTech will license certain technology rights to the new entity and receive a minority stake, but has ruled out any ongoing financial support. A binding agreement is expected by mid-year. The board is now searching for successors, and the market’s initial reaction in March was sharp: the stock hit its year low on the day the exit was announced. Analysts at Leerink Partners described the leadership change as a logical step for a maturing company but warned that a perceived vacuum could weigh on sentiment in the short term.

Counterbalancing the uncertainties is a deepening oncology pipeline. In the first quarter, BioNTech launched five new registration trials for pumitamig. Meanwhile, early data for gotistobart showed a 54% reduction in the risk of death among lung cancer patients compared with standard chemotherapy, offering some of the most tangible proof of concept yet for the company’s shift beyond infectious disease. A flurry of additional clinical readouts are expected by the end of the year, including further interim efficacy data on gotistobart.

The restructuring is expected to generate annual savings of around €500 million by 2029, money that will be redirected toward the oncology pipeline. BioNTech hopes that asset sales – particularly real estate and equipment from the closed factories – will provide an additional financial lift. For now, the stock reflects the transitional strain. On Wednesday, shares slid 1.07% to €78.85, extending a monthly decline of 6.41%. At €79.70, the stock remains well below its long-term moving average, with only a modest recovery from the trough set on the day Sahin and Türeci announced their departure.

BioNTech at a turning point? This analysis reveals what investors need to know now.

The coming months will test whether BioNTech can execute on three fronts simultaneously: wind down manufacturing without operational disruption, install a credible new leadership team, and deliver oncology data convincing enough to sustain a valuation built on hope rather than vaccine revenue. The cash cushion provides time – but the clock is ticking toward 2027.

Ad

BioNTech Stock: New Analysis - 13 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECHS | boerse | 69326393 |